Potentially disruptive technologies
We have three highly differentiated technologies focused on next generation anthracycline, immune/transcription modulators and metabolism/glycosylation inhibitors.
“The unprecedented events unfolding in 2020 have, of course, touched all of us in profound ways. In our case, the unique opportunity we have to develop a potential therapy for COVID-19 has been a game-changing event for all Moleculin stakeholders. While our focus on generating important clinical data in our AML trials, expanding clinical testing of Annamycin in lung metastases, building off of the early proof-of-concept success we’ve seen with WP1220 in CTCL and continuing to support GBM clinical trials with WP1066 has not changed, we are now expanding our team to include experts in virology to ensure that we move WP1122 into a COVID-19 clinical trial as quickly as possible. These are indeed challenging times, but they also represent an even greater opportunity for Moleculin to save lives.”
On April 3, 2019, Moleculin announced that preclinical data supporting activity of its STAT3-inhibiting Immune/Transcription Modulators was presented at the 2019 AACR Annual Meeting.
On October 29, 2019, Moleculin announced the presentation of a poster at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference documenting the high activity of Annamycin against AML.
On December 19, 2019, Moleculin announced the presentation of a poster at the San Antonio Breast Cancer Symposium demonstrating Annamycin’s unusually high lung uptake and anticancer activity against lung metastases of multiple solid tumors.